Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesc Bosch

Showing results (121-130 of 170) with videos related to

Pageof 17
Sort By:
Blood|October 15, 2013
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemiaPau Abrisqueta, Neus Villamor, María José Terol, et al.
Haematologica|March 13, 2025
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemiaDaniel Medina-Gil, Laura Palomo, Víctor Navarro, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
British Journal of Haematology|April 19, 2024
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasmsSara Torres-Esquius, Francisco Beas, Tzu Hua Chen-Liang, et al.
American Journal of Hematology|May 8, 2023
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasmsMoraima Jiménez, Candela Fernández-Naval, Víctor Navarro, et al.
Leukemia & Lymphoma|July 22, 2017
Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemiaIsabel González-Gascón Y Marín, María Hernández-Sanchez, Ana Eugenia Rodríguez-Vicente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 3, 2025
Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospectsPilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Blood Advances|November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomasElise A Chong, Elicia Penuel, Ellen B Napier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
Pageof 17

Showing results (121-130 of 170) with videos related to

Sort By:
Pageof 17
Blood|October 15, 2013
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemiaPau Abrisqueta, Neus Villamor, María José Terol, et al.
Haematologica|March 13, 2025
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemiaDaniel Medina-Gil, Laura Palomo, Víctor Navarro, et al.
Bone Marrow Transplantation|June 24, 2024
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignanciesMaria Laura Fox, Irene García-Cadenas, Victor Navarro, et al.
British Journal of Haematology|April 19, 2024
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasmsSara Torres-Esquius, Francisco Beas, Tzu Hua Chen-Liang, et al.
American Journal of Hematology|May 8, 2023
Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasmsMoraima Jiménez, Candela Fernández-Naval, Víctor Navarro, et al.
Leukemia & Lymphoma|July 22, 2017
Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemiaIsabel González-Gascón Y Marín, María Hernández-Sanchez, Ana Eugenia Rodríguez-Vicente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 3, 2025
Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospectsPilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Blood Advances|November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomasElise A Chong, Elicia Penuel, Ellen B Napier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
Pageof 17